PDT Partners’s Pacific Biosciences PACB Stock Holding History

PDT Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,711	Closed	-$511K	–	854
2020 Q4	$511K	Buy	+19,711	New	+$335K	0.03%	448
2020 Q3	–	Sell	-17,696	Closed	-$61K	–	826
2020 Q2	$61K	Buy	+17,696	New	+$60.2K	﹤0.01%	644
2018 Q4	–	Sell	-286,310	Closed	-$1.55M	–	503
2018 Q3	$1.55M	Buy	286,310 +118,510	+71%	+$509K	0.06%	269
2018 Q2	$596K	Hold	167,800	–	–	0.02%	381
2018 Q1	$344K	Sell	167,800 -89,400	-35%	-$232K	0.01%	482
2017 Q4	$679K	Sell	257,200 -137,600	-35%	-$482K	0.02%	395
2017 Q3	$2.07M	Hold	394,800	–	–	0.07%	272
2017 Q2	$1.41M	Buy	394,800 +146,423	+59%	+$590K	0.06%	297
2017 Q1	$1.28M	Buy	+248,377	New	+$1.22M	0.07%	289

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's PACB Position: Q1 2021 in Review

PDT Partners sold out of Pacific Biosciences (PACB) in Q1 2021, closing a stake of 19,711 shares — an estimated $511K sold.

PDT Partners first reported a position in PACB in Q1 2017 and held it in 9 quarters. The position peaked at $2.07M in Q3 2017. 263 funds tracked by Wall St. Rank hold PACB as of Q1 2021.

PDT Partners reported no remaining Pacific Biosciences position as of Q1 2021 after selling out during the quarter.
PDT Partners sold 19,711 Pacific Biosciences shares in Q1 2021, an estimated $511K.
PDT Partners first reported a position in Pacific Biosciences in Q1 2017 and held it in 9 quarters.
PDT Partners's Pacific Biosciences position peaked at $2.07M in Q3 2017.
263 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2021.

Based on PDT Partners's 13F filing for Q1 2021, filed 17 May 2021.